Auromed Ltd - Stock Valuation and Financial Performance

BSE: 532103 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Auromed

M-Cap below 100cr DeciZen not available

Auromed stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
0 Cr.
52-wk low:
0
52-wk high:
0

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Auromed:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'02Mar'03Mar'04Mar'05TTM
ROCE % 0%0.1%0.2%0.9%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 0.40.40.41.52
Sales YoY Gr.-8.1%-2.5%284.6%-
Adj EPS 0000.10.1
YoY Gr.-NA100%350%-
BVPS (₹) 9.49.49.69.810.1
Adj Net
Profit
0000.10
Cash Flow from Ops. -0.10-0.10.2-
Debt/CF from Ops. -0.3-1.1-0.10.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANA59.5%284.6%
Adj EPS NANANA350%
BVPSNANA1.4%1.9%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'02Mar'03Mar'04Mar'05TTM
Return on
Equity %
00.10.20.90.9
Op. Profit
Mgn %
0.50.7-6.36.6NAN
Net Profit
Mgn %
0.30.42.13.13.1
Debt to
Equity
0000-
Working Cap
Days
0160218710
Cash Conv.
Cycle
05791310

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Auromed Ltd.

Standalone Consolidated
TTM EPS (₹) 0.1 -
TTM Sales (₹ Cr.) 1.5 -
BVPS (₹.) 10.1 -
Reserves (₹ Cr.) - -
P/BV 0.00 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 0.00 / 0.00
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 0
Equity (₹ Cr.) 5.1
Face Value (₹) 10
Industry PE 48.5

Management X-Ray of Auromed:

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Auromed

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'02Mar'03Mar'04Mar'05
Sales0.370.400.391.50
Operating Expenses 0.370.390.411.40
Manufacturing Costs0.050.060.040.19
Material Costs0.220.250.270.99
Employee Cost 0.040.040.050.06
Other Costs 0.050.040.050.15
Operating Profit 00-0.020.10
Operating Profit Margin (%) 0.5%0.7%-6.3%6.6%
Other Income 000.070.10
Interest 0000
Depreciation 000.030.12
Exceptional Items 0000
Profit Before Tax 000.010.07
Tax 0000.03
Profit After Tax 000.010.05
PAT Margin (%) 0.3%0.4%2.1%3.1%
Adjusted EPS (₹)0.00.00.00.1
Dividend Payout Ratio (%)0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'02Mar'03Mar'04Mar'05

Equity and Liabilities

Shareholders Fund 3.403.405.125.17
Share Capital 3.393.395.115.11
Reserves 00.010.010.06
Minority Interest0000
Debt0.010.020.010.02
Long Term Debt0.010.020.010.02
Short Term Debt0000
Trade Payables0.050.050.010
Others Liabilities 000.020.05
Total Liabilities 3.473.475.165.24

Fixed Assets

Gross Block000.681.24
Accumulated Depreciation000.030.16
Net Fixed Assets000.651.09
CWIP 2.752.733.653.33
Investments 0000
Inventories0.110.120.120.14
Trade Receivables0000
Cash Equivalents 000.010.01
Others Assets0.610.610.720.67
Total Assets 3.473.475.165.24

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'02Mar'03Mar'04Mar'05
Cash Flow From Operating Activity -0.05-0.02-0.100.23
PBT 000.010.05
Adjustment 000.030.20
Changes in Working Capital -0.05-0.02-0.14-0.02
Tax Paid 0000
Cash Flow From Investing Activity 0.050.01-1.60-0.24
Capex 00-0.68-0.56
Net Investments 0000
Others 0.050.01-0.920.33
Cash Flow From Financing Activity 001.710.01
Net Proceeds from Shares 001.720
Net Proceeds from Borrowing 0000
Interest Paid 0000
Dividend Paid 0000
Others 00-0.010.01
Net Cash Flow 000.010
PARTICULARSMar'02Mar'03Mar'04Mar'05
Ratios
ROE (%)0.030.060.20.95
ROCE (%)0.050.090.321.49
Asset Turnover Ratio0.110.110.090.29
PAT to CFO Conversion(x)N/AN/A-104.6
Working Capital Days
Receivable Days0000
Inventory Days10910811832
Payable Days8975392

Auromed Ltd Stock News

Auromed Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Auromed on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Auromed stood at ₹0.00.
The latest P/E ratio of Auromed as of 01-Jan-1970 05:30 is 0.00.
The latest P/B ratio of Auromed as of 01-Jan-1970 05:30 is 0.00.
The 52-week high of Auromed is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Auromed is ₹1.50 ( Cr.) .

About Auromed Ltd

Auromed was incorporated in March 1995 as a public limited company promoted by D Srinivasvaradhan. The company is in the process of establishing a multipurpose bulk drug and pharmaceutical manufacturing plant at Guduvancheri in Tamilnadu. It came out with a public issue in June 1996 to part-finance this project. The company manufactures bronopol BP, norfloxacin BP and diclofenac sodium BP, betaine base and betaine hydrochloride BP.

Bronopol will be exported to European countries for which the company has firm marketing tie-up with Transtech International, UK; Herman Gshutte & Co, Germany and Pharmaco, Germany. Betaine base and betaine hydrochloride will also be exported through marketing agreement with Perry Pharmaceuticals, UK; Lab-Tech Pharma, Switzerland and Webster Pharma Technique, France . Norfloxacin and diclofenac sodium will be marketed in the domestic market.

The registered office of the company is located at Srinilayam 1, Kannaiah Street, T Nagar Chennai in Tamil Nadu.

Read More Read Less
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.